Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
21SEP

IMU raises £40m to read blood

2 min read
16:52UTC

IMU Biosciences closed an oversubscribed £40m Series A on 2 June, co-led by IQ Capital and Molten Ventures, with the British Business Bank co-investing on its second UK life-sciences cap table inside a fortnight.

← Back to Nscale takes $103.4bn of contracts to NYSEJump to analysis ↓
TechnologyDeveloping
Key takeaway

State capital is now a routine equity co-investor on British biotech cap tables beside specialist funds.

IMU Biosciences closed an oversubscribed £40m ($53m) Series A on Tuesday 2 June. IQ Capital and Molten Ventures co-led, with the British Business Bank (BBB) co-investing. Oversubscribed means investors sought more shares than the company offered. The platform extracts more than 100 million immune-system data points from a single blood sample, so one routine draw could replace a battery of separate immune tests. 1

The BBB had put £12m into Cytospire's £61m Series A in May and £50m into the Longwall deep-tech fund . Its £6.6bn expanded mandate lets it lead and co-invest directly in startups rather than backing them only through fund intermediaries.

That pattern reframes what UK state capital does at this stage. A development bank acting as a backstop appears when private money is absent; the BBB is appearing precisely where private money is already present, sitting beside IQ Capital and Molten on a priced biotech round. State capital is becoming a recurring line on British biotech cap tables rather than a substitute for the funds it sits beside.

Deep Analysis

In plain English

A standard blood test measures perhaps 20-50 different immune markers at once. IMU Biosciences has built a platform that measures over 100 million data points from a single blood sample, a four-to-five order of magnitude jump in resolution. Immune system data is medically useful because immune patterns appear early in many diseases, sometimes before other symptoms. At this density, IMU can identify correlations that simpler assays miss entirely: which patients will respond to a specific immunotherapy, or which immune signatures predict disease progression. The £40m raised funds the clinical validation studies needed to convert that data density into diagnostic products that hospitals and pharmaceutical companies will pay for.

What could happen next?
  • Precedent

    The BBB's third direct life-sciences co-investment in six weeks (Cytospire, Quantum Motion, IMU) establishes a pattern: UK state capital now participates routinely in private biotech rounds as a minority co-investor alongside specialist VCs.

  • Opportunity

    The 100-million-data-point density creates a pharmaceutical partnership opportunity: drug companies running immunology trials can pay per-assay fees for immune profiling at a resolution unavailable elsewhere.

Sources:UK Tech News
Mentions:IQ Capital →British Business Bank →Cytospire Therapeutics →Longwall Ventures →IMU Biosciences →Molten Ventures →
First Reported In

Update #7 · OQC's £260m sets European quantum record

UK Tech News· 7 Jun 2026
Read original →
Causes and effects
Caused by
Cytospire's £61m oncology Series A oversubscribed
BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.
Occurred 5 May 2026
Read story →
State £50m backs the tier funds skip
BBB's £50m Longwall deep-tech fund cornerstone in May is part of the same expanded mandate that brought BBB onto IMU's cap table directly.
Occurred 27 May 2026
Read story →
Jobs plan targets the lab-skills gap
The plan addresses the same staffing gap IMU Biosciences' £40m AI-biotech round in June assumed was solved.
Occurred 9 Jul 2026
Read story →
This Event
IMU raises £40m to read blood
The state bank's repeat direct co-investment shows it acting as a routine equity partner in British biotech, not a lender of last resort.
Led to
Neubond seed is Japan VC's UK first
IMU Biosciences' £40m Series A is part of the UK-research-producing-companies pattern Neubond's Japanese-funded seed continues.
Occurred 15 Jun 2026
Read story →
Alchemab wins Bank's record £25m cheque
IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.
Occurred 9 Jul 2026
Read story →
Different Perspectives
Nscale and Open Cosmos
Nscale and Open Cosmos
Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.
The Entrepreneurs Network
The Entrepreneurs Network
The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.
New Economics Foundation
New Economics Foundation
The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.
Competition and Markets Authority
Competition and Markets Authority
The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.